Recent microarray technologies have enabled the molecular classification of breast cancer into four subtypes: estrogen receptorpositive/luminal-like, human epidermal growth factor receptor 2-overexpressing (Her2/ErbB2-positive), normal-like, and basal- 
Forkhead box C1 is a transcription factor belonging to the forkhead box family that plays multiple functions in the formation of vasculature and organic development during embryogenesis. 6, 7 It is also involved in cell growth and invasion as well as regulation of metabolism, and longevity. 8, 9 In vivo, FOXC1 knockout mice die at birth and have anterior eye segment malformations. 10, 11 Accumulating evidence has shown that FOXC1 exerts an important function in cancer tumorigenesis and progression. Overexpression of FOXC1 increases cell invasiveness and promotes distal metastasis in many cancer types. 4, [12] [13] [14] Further examinations show that FOXC1 is a potential biomarker for BLBC and predicts poor survival in breast cancer patients. 4, 15, 16 Forkhead box C1 promotes BLBC cell proliferation and invasion through regulating NF-κB signaling or the expression of MMP7, which is downstream of NF-κB. 17, 18 Forkhead box C1 activates Smoothenedindependent Hedgehog signaling and enhances BLBC cancer stem cell properties. 15 In addition, FOXC1 induces epithelial-mesenchymal transition through inhibition of E-cadherin expression in mammary epithelial cells. 19, 20 The mechanisms of how FOXC1 exerts these effects are not well understood. Therefore, we chose two cell lines in this study to examine the potential mechanisms and to determine whether FOXC1 could be a promoter for TNBC.
CXC chemokine receptor-4, a G protein-coupled cell surface receptor with seven transmembrane-spanning domains, selectively binds the stromal cell-derived factor 1 to play a crucial function in various cancers, including esophageal cancer, ovarian cancer, gastric cancer, and breast cancer. 21, 22 Additionally, CXCR4 is overexpressed in various tumor cells and mediates cell survival, proliferation, and migration. [23] [24] [25] Recent researches disclose that CXCR4 is a crucial regulator facilitating breast cancer cell metastasis. 22, [26] [27] [28] [29] Moreover, inhibition of CXCR4 in basal-like MDA-MB-231 breast cancer cells blocks breast cancer metastasis to the lung. 27, 30 Our group reported previously that CXCR4 expression is associated with TNBC distal metastasis. 31 Previous works suggested that FOXC1 could transcriptionally enhance CXCR4 expression in mouse embryonic endothelial cells. 32 This study aims to reveal whether FOXC1 could promote the metastatic capability of TNBC cells through regulating the expression of CXCR4. We discovered that overexpression of FOXC1 in MDA-MB-231 cells significantly enhanced, whereas knockdown of FOXC1 in BT549 cells significantly reduced, the capabilities of TNBC cell invasion and motility in vitro and metastasis to the lung in vivo, when compared to their respective control cells. We then determined that FOXC1 enhanced the expression of CXCR4, probably through transcriptional upregulation of CXCR4. Moreover, we found that CXCR4 might mediate FOXC1-induced capabilities of invasion and motility in BLBC cells. Collectively, these data suggest that FOXC1 promotes TNBC cells metastasis by upregulating expression of CXCR4.
| MATERIAL S AND ME THODS

| Cell culture and specimens
The human breast cancer cell lines MDA-MB-231 and BT549 were obtained from ATCC (Manassas, VA, USA) and cultured according to the instructions of the manufacturer. These cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% FCS.
Seven TNBC specimens frozen in liquid nitrogen were selected from An siRNA targeting CXCR4 and a control scramble siRNA were purchased from GenePharma (Shanghai, China). The sequence for si-CXCR4 was 5′-UAAAAUCUUCCUGCCCACCdTdT-3′. 30 The nonspecific scramble siRNA (5′-UUCUCCGAACGUGUCACGUdTdT-3′) was used as the negative control. The human FOXC1 shRNA sequence is CCGGCAAGAAGAAGGACGCGGTGAACT-CGAGTTCAC CGCGTCCTTCTTCTTGTTTTTG, corresponding to 523-543 of the FOXC1 cDNA.
| Colony formation assay
Cells (400 cells/well) were seeded onto 6-well plates. After incubation at 37°C for 14 days, the colonies were fixed with methanol for 20 minutes, stained with 0.4% crystal violet, and photographed using phase-contrast light microscopy. An accumulated growth of more than 50 cells was identified as the formation of a colony. We used ImageJ software (NIH, Bethesda, MD, USA) to calculate the colony numbers.
| Wound healing assay
MDA-MB-231 cells were seeded at a density of 4 × 10 4 cells per well in 96-well plates. After treatment with 40 μmol/L AMD3100, the monolayer of cells was scratched with a 10-μL plastic pipette tip to create a uniform wound. The wound width was then examined after 24 hours of incubation under a phase-contrast microscope (IX51; Olympus, Tokyo, Japan). Photographs of at least 3 random fields were taken, and the cell migration ability was expressed by the closure of the gap distance. The distance was measured by ImageJ software. Basic vector (Promega).
| Migration and invasion assays
| Real-time PCR
Total RNA was extract using TRIzol (Invitrogen), and reverse transcription was carried out using an RT-PCR kit (RR047A and RR820A; Takara, Beijing, China) according to the manufacturer's instructions; 
| Immunoblotting analysis
Equal amount of proteins (50 μg) were separated onto SDSpolyacrylamide gels and were electrotransferred to PVDF membranes (Millipore, Bedford, MA, USA). The membranes were immunoblotted overnight at 4°C with primary antibodies, followed 
| Chromatin immunoprecipitation-coupled RT-PCR
Chromatin immunoprecipitation was carried out using a kit ( 
| In vivo metastasis assay
This animal experiment for testing the effect of FOXC1 on BLBC cells metastasis to the lung was approved by the Animal Care Committee of Shantou University Medical College and was undertaken in accordance with national and international guidelines. Cells described in the figure legend were suspended in a density of 1 × 10 7 per mL PBS; 0.1 mL cell suspension was injected into the tail veins of 6-week-old SCID mice (Vital River Laboratory Animal Technology, Beijing, China). Eight weeks later, the mice were killed and the lungs were fixed in 10% formalin for tissue sectioning. The numbers of lung metastatic nodules were counted by H&E staining. Three independent experiments were carried out. *P < .05. F, Overexpression of FOXC1 significantly increased cell migration and invasion compared with the control group. *P < .05, n = 3. G, Results of colony formation assays show that FOXC1 knockdown reduced the numbers of formed colonies. *P < .05, n = 3. H, Results of colony formation assays showed that FOXC1 overexpression increased the numbers of formed colonies. *P < .05, n = 3
| Statistical analyses
Data were reported as mean values ± SEM. Differences were assessed for statistical significance by a two-tailed t test. All statistical analyses were carried out using SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA). P values < .05 were considered to be statistically significant. Figure 1F ). In addition, we examined whether FOXC1
| RE SULTS
could influence the in vitro clonogenic capacities of BLBC cells and revealed that FOXC1 knockdown reduced the colonyforming efficiency (86.33 ± 17.16 vs 52 ± 9.64, P < .05; Figure 1G ) of BT549 cells, whereas FOXC1 overexpression improved the colony-forming efficiency (56.35 ± 5.13 vs 74.67 ± 8.34, P < .05; Figure 1H ) of MDA-MB-231 cells. These data suggest that FOXC1 could enhance the in vitro metastatic capabilities of TNBC cells.
| Forkhead box C1 facilitates TNBC cells metastasis to the lung
We 
| Forkhead box C1 transactivates the expression of CXCR4
CXC chemokine receptor-4 is associated with distal metastasis in BLBC, 31 and is transcriptionally regulated by FOXC1 in vascular endothelial cells in mice. 32 Forkhead box C1 might also regulate the expression of CXCR4 in breast cancer cells. To examine this hypothesis, 
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Luciferase a 1.7-kb promoter region of human CXCR4 (−1731 to +18) containing a putative FOXC1 binding site ( Figure 4A ). Reporter gene assays showed that the CXCR4 promoter activity normalized to that of the cotransfected Renilla luciferase was reduced by approximately 70% in BT549-shFOXC1 cells when compared with that in BT549-shNC cells ( Figure 4B ). However, the relative promoter activity was 3-fold higher in 231-FOXC1 than in 231-pCMV6 cells ( Figure 4C ). To confirm that CXCR4 is a direct target gene of FOXC1, we carried out ChIP assays using a polyclonal Ab against FOXC1 in BT549 cells. As shown in Figure 4D , relative enrichment of CXCR4 promoter was markedly increased compared with the control normal goat IgG by quantitative PCR. These results are in line with those shown in Figure 3 , further suggest that FOXC1 could upregulate the expression of CXCR4 at the transcription level, at least partially.
| Inhibition of CXCR4 suppressed cell migration, invasion, and metastasis
To identify the function of CXCR4, we chose AMD3100, a selective CXCR4 antagonist to treat MDA-MB-231 cells, and found that expression of CXCR4 was inhibited by AMD3100 ( Figure 5A ). Wound healing assays showed that AMD3100 could suppress cell migration compared with the control group ( Figure 5B ). The zebrafish embryos were used to monitor human tumor cell invasion and metastasis in vivo. AMD3100 treatment decreased the ability of BT549 cells to metastasize to the trunk region of the zebrafish embryo ( Figure 5C ).
Quantification analysis showed that the intensity of distal metastatic tumor cells treated with AMD3100 in the trunk was markedly lower than the intensity of the control cells ( Figure 5D ). These findings further verified that inhibition of CXCR4 reduced cancer cell metastasis.
| CXC chemokine receptor-4 mediates the FOXC1 enhancement of TNBC invasive capabilities in vitro
As CXCR4 has been reported to participate in the growth, migration, and invasion of cancer cells, [34] [35] [36] we further investigated whether FOXC1 expression would affect cell migration and invasion through CXCR4. First, western blot results showed that CXCR4 expression was downregulated by siRNA, and the inhibitory effect F I G U R E 5 AMD3100 attenuated triple-negative breast cancer cell migration, invasion, and metastasis. A, CXC chemokine receptor-4 (CXCR4) expression was inhibited when treated with AMD3100 for 48 hours. *P < .05, n = 3. B, AMD3100 suppresses basal-like breast cancer cell migration in an in vitro wound healing assay. *P < .05, n = 3. Scale bar = 200 μm. C, Intravital fluorescence microscopy images of 5 days postfertilization zebrafish embryos taken 3 days postinjection (3 dpi). Scale bar = 500 μm. Bottom panels show a higher magnification of the boxes. Scale bar = 100 μm. D, Quantification of intensity of disseminated and metastatic cells in the primary tumor surroundings and in the trunk regions at 3 dpi. *P < .05, n = 22 
| D ISCUSS I ON
Breast cancer is a heterogeneous disease and comprises several molecular subtypes. TNBC, one of subtypes, is the most aggressive and has no targetd therapies currently. 1 The forkhead box transcription factor FOXC1, an evolutionarily conserved transcription factor, mediates multiple biological processes, including metabolism, differentiation, development, and proliferation, 37 and participates in the progression of tumors. 38 Previous studies showed that FOXC1 is a special biomarker for BLBC and promotes cell proliferation and migration. 4, 16 In this study, we also verify that FOXC1 enhances cell migration and invasion. We further show that FOXC1
improves the ability of cell colony formation in TNBC cells. Previous reports have shown that FOXC1 enhances the ability of cell migration and invasion in breast cancer. 4, 18, 39 In vivo studies reported that FOXC1-overexpressing cells have increased tumor growth and lung metastasis in nude mice, whereas FOXC1 knockdown completely suppressed tumorigenesis and lung metastasis. 13, 15 These results show that FOXC1 plays a crucial role in TNBC. A recent study
showed that FOXC1 exerts its promoting function through the NF-κB signaling pathway in BLBC. 18 Matrix metalloprotease-7, one of the downstream targets of NF-κB, is a novel regulatory mechanism that FOXC1 promotes in BLBC invasion and metastasis. 17 However, the regulatory mechanism of FOXC1 in TNBC remains to be elucidated.
In our studies, overexpression of FOXC1 could increase CXCR4 mRNA and protein expression in MDA-MB-231 cell. Conversely, inhibition of FOXC1 could reduce CXCR4 mRNA and protein expression.
The level of FOXC1 expression was correlated with the expression of CXCR4 in clinical samples. In addition, the luciferase assay further showed that FOXC1 increases CXCR4 transcription activity. A recent study found that FOXC1 directly regulates CXCR4 expression by activating its promoter in mouse embryonic endothelial cells. 32 Indeed, our ChIP assay also identified that FOXC1 could bind the CXCR4 promoter and increase CXCR4 promoter fold enrichment in breast cancer.
Furthermore, FOXC1-deficient endothelial cells show lower motility ability activated by CXCL12. 32 Interestingly, FOXO1, a member of 40 These results suggested that FOXC1 binds the CXCR4 promoter to regulate CXCR4 transcription, which indicates that CXCR4 was a downstream target of FOXC1.
Chemokine receptor-4, a G protein-coupled receptor that displayed 7 transmembrane helical domains, plays important functions in breast cancer. Studies showed that CXCR4 was expressed highly in both primary and metastatic breast cancer, but had a low level or even no expression in normal breast tissue. 28 Our results showed that inhibition of CXCR4 could block cell migration in vitro. In a zebrafish tumor model, we found that the cells treated with AMD3100
showed fewer metastatic tumor cells in the trunk region of the zebrafish embryos. This is consistent with reports that inhibition of CXCR4
in MDA-MB-231 cells reduced breast cancer metastases to the lung and lymph nodes in a mouse model. 27, 30 High expression of CXCR4 in basal-like tumor patients resulted in higher recurrence incidence and related death compared with patients with low expression of CXCR4. 41, 42 Hence, higher CXCR4 expression might predict a worse survival rate in patients with BLBC. Previous studies and our present data showed that FOXC1 promotes breast cancer cell migration and invasion. However, the mechanism by which FOXC1 enhanced CXCR4 expression remains unknown in TNBC. Our study shows that inhibi- 
